Aduro Biotech Inc. (NASDAQ:ADRO)‘s stock had its “outperform” rating restated by equities research analysts at FBR & Co in a research report issued on Monday. They presently have a $20.00 price objective on the stock. FBR & Co’s target price indicates a potential upside of 40.85% from the company’s previous close.

A number of other analysts have also commented on ADRO. Canaccord Genuity set a $30.00 price objective on Aduro Biotech and gave the stock a “buy” rating in a research report on Monday, October 24th. Leerink Swann set a $14.00 target price on Aduro Biotech and gave the stock a “buy” rating in a research report on Monday, October 24th. Roth Capital restated a “buy” rating and set a $20.00 target price (down from $22.00) on shares of Aduro Biotech in a research report on Thursday, October 27th. Finally, Zacks Investment Research lowered Aduro Biotech from a “hold” rating to a “sell” rating in a research report on Monday, July 18th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $21.33.

Analyst Recommendations for Aduro Biotech (NASDAQ:ADRO)

Aduro Biotech (NASDAQ:ADRO) opened at 14.20 on Monday. Aduro Biotech has a 12-month low of $7.26 and a 12-month high of $34.95. The firm’s market cap is $953.98 million. The company has a 50-day moving average price of $12.41 and a 200-day moving average price of $12.86.

Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.54) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.45) by $0.09. The firm earned $3.79 million during the quarter, compared to analyst estimates of $3.99 million. Aduro Biotech had a negative return on equity of 23.45% and a negative net margin of 72.04%. Aduro Biotech’s revenue for the quarter was down 79.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.01 earnings per share. On average, analysts predict that Aduro Biotech will post ($1.32) earnings per share for the current year.

In other news, insider Thomas W. Dubensky sold 25,000 shares of Aduro Biotech stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $14.03, for a total transaction of $350,750.00. Following the transaction, the insider now owns 16,407 shares in the company, valued at approximately $230,190.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jennifer Lew sold 6,360 shares of Aduro Biotech stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $14.95, for a total value of $95,082.00. Following the transaction, the insider now owns 48,955 shares in the company, valued at approximately $731,877.25. The disclosure for this sale can be found here. Insiders own 6.50% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in ADRO. Acrospire Investment Management LLC boosted its position in Aduro Biotech by 27.6% in the second quarter. Acrospire Investment Management LLC now owns 9,700 shares of the company’s stock valued at $110,000 after buying an additional 2,100 shares during the period. BlackRock Group LTD boosted its stake in Aduro Biotech by 108.1% in the third quarter. BlackRock Group LTD now owns 11,031 shares of the company’s stock valued at $136,000 after buying an additional 5,729 shares during the last quarter. BlackRock Inc. boosted its stake in Aduro Biotech by 1,850.5% in the second quarter. BlackRock Inc. now owns 12,600 shares of the company’s stock valued at $142,000 after buying an additional 11,954 shares during the last quarter. Parametric Portfolio Associates LLC purchased a new stake in Aduro Biotech during the second quarter valued at approximately $143,000. Finally, Wells Fargo & Company MN boosted its stake in Aduro Biotech by 1.1% in the third quarter. Wells Fargo & Company MN now owns 12,258 shares of the company’s stock valued at $152,000 after buying an additional 139 shares during the last quarter. Institutional investors and hedge funds own 29.41% of the company’s stock.

Aduro Biotech Company Profile

Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.

5 Day Chart for NASDAQ:ADRO

Receive News & Stock Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related stocks with our FREE daily email newsletter.